lumiracoxib + methotrexate

This is a combination of two drugs: lumiracoxib, a selective cyclooxygenase-2 (COX-2) inhibitor non-steroidal anti-inflammatory drug (NSAID), and methotrexate, an antimetabolite and immunosuppressant. Lumiracoxib acts by inhibiting prostaglandin synthesis via selective inhibition of the COX-2 enzyme, providing anti-inflammatory and analgesic effects primarily for osteoarthritis. Methotrexate is used as a disease-modifying antirheumatic drug (DMARD) in conditions such as rheumatoid arthritis and various cancers; its mechanism involves inhibition of dihydrofolate reductase, leading to suppression of DNA synthesis in rapidly dividing cells, as well as interruption of adenosine pathways contributing to its anti-inflammatory effects. The combination may be considered in rheumatologic practice for patients requiring both NSAID therapy for pain/inflammation and DMARD therapy for disease control[1][2][3][4].